Condition: Lung Cancer · Sponsor: Snipe Medical
A Prospective, open label, multi center, single arm, First in Human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumor resection
This description comes directly from the study's public registry record.
Emily Ben Shlomo · 972523212687 · emily.benshlomo@clalit.org.il
Always discuss trial participation with your own doctor first.
| Meir Medical Center | Kfar Saba, Israel | Recruiting |
| University Hospital Complex of Salamanca | Salamanca, Spain | Recruiting |
| Royal Brompton Hospital | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06423690